Expression and purification of recombinant G protein-coupled receptors: A review

Daniel N. Wiseman, Abigail Otchere, Jaimin H. Patel, Romez Uddin, Naomi L. Pollock, Sarah J. Routledge, Alice J. Rothnie, Cathy Slack, David R. Poyner, Roslyn M. Bill, Alan D. Goddard

School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK
University of Birmingham, Birmingham, B15 2TT, UK

A R T I C L E   I N F O

Keywords:
Expression
Purification
GPCR
SMALP
Review

A B S T R A C T

Given their extensive role in cell signalling, GPCRs are significant drug targets; despite this, many of these receptors have limited or no available prophylaxis. Novel drug design and discovery significantly rely on structure determination, of which GPCRs are typically elusive. Progress has been made thus far to produce sufficient quantity and quality of protein for downstream analysis. As such, this review highlights the systems available for recombinant GPCR expression with consideration of their advantages and disadvantages, as well as examples of receptors successfully expressed in these systems. Additionally, an overview is given on the use of detergents and the styrene maleic acid (SMA) co-polymer for membrane solubilisation, as well as purification techniques.

1. Introduction

As the largest family of membrane proteins in the human genome, G protein-coupled receptors (GPCRs) are widely studied due to their involvement in normotypical and pathological cell signalling profiles [1]. Characteristically, as shown in Fig. 1, these seven-transmembrane receptors undergo a conformational change upon activation by a ligand, allowing propagation of signalling cascades within the cell [2].

Understanding the relationship between a GPCR’s structure and function will aid further development of ortho- and allosteric molecules against these receptors to affect their pharmacology. While approximately half of all drugs target GPCRs, this is only reflected in a 5% coverage of these receptors, providing significant scope for further structure-based novel drug discovery [4].

While the structure of some GPCRs have been successfully determined, many challenges remain in this field. These include the concepts of homo-dimerization, heteromeric protein-protein interactions and the structural complexity of important motifs [5] – of note, the folding and flexibility of the ligand-binding domain of family B GPCRs [6]. While computational biology has greatly enhanced the versatility of studying GPCR structures [7], classical techniques are also often employed including x-ray crystallography [8], cryo-electron microscopy [9] and nuclear magnetic resonance spectroscopy [10]. A significant drawback to these methods lies in the initial requirement for a high yield and purity of mature, folded target protein.

These challenges have propelled the development and implementation of recombinant membrane protein expression, solubilisation and purification systems over the last two decades - contributing, in no small part, to the increase in resolved structures of membrane proteins in the same time-frame [11]. This review will provide a current summary of the methodology, benefits and drawbacks of the expression systems available to GPCR researchers (Table 1), as well as an overview of applicable solubilisation and purification techniques.

2. Expression systems

2.1. E. coli

Native expression of GPCRs is well-known to be restricted to eukaryotic organisms [12] yet E. coli has proved an attractive host for expression and purification of a subset of receptors [13]. E. coli has become a laboratory workhorse for a number of reasons. Firstly,
decades of work have led to well-characterised, rapidly growing cells which are easy to culture and strains have been optimised for protein expression, including membrane protein-specific strains [14]. *E. coli* can be easily grown across a range of scales allowing fermentation to produce large quantities of protein, although it should be noted that there is not always a linear relationship between culture volume and product yield [14]. The genetic tractability of *E. coli* allows a variety of expression plasmids to be used to tune protein expression levels. This can be particularly important with membrane proteins when saturation of the translocon can be a rate-limiting step [13,15]. Indeed, high level expression can lead to formation of inclusion body and refolding of GPCRs from such environments has met with limited success [16]. Some of these problems can be overcome with judicial strain selection and expression at lower temperatures [17]. However, due to its prokaryotic nature, *E. coli* does not possess a number of features that can be essential for GPCR function. There is a lack of post-translational modification, including glycosylation, which can be essential for ligand binding [18]. Despite this, there are several examples of active receptor expression [19–34] including the neurotensin and cannabinoid CB2 receptors. The use of *E. coli* in this sense can also be supported by the ability of deglycosylated receptors [35] to bind ligand, and protein engineering for stability [36]. Additionally, the lipid membrane environment may not include essential components such as cholesterol [37] and contains a very different lipidome to eukaryotic cells – there is clear evidence for lipid-dependent GPCR activity [38].

Despite these clear limitations [39], there have been a number of reports of GPCRs being successfully expressed in *E. coli* [19–34]. Unmodified GPCRs tend to have low stability and may aggregate in such systems [33]. A key strategy for successful expression and correct folding of GPCRs in *E. coli* is the use of fusion partners [40]. These serve both to direct the correct insertion of the receptor into the membrane whilst also increasing its overall solubility, thereby aiding both expression and purification [26]. Additionally, strategies such as selective mutagenesis to introduce stabilising mutations and the use of insertions or truncations has proven successful in some cases [17,33]. Indeed, the genetic tractability of *E. coli* can be used to select for variants with increased stability and expression even for relatively intractable receptors [41–43].

There are a number of advantages of the use of *E. coli* for downstream applications. It is relatively easy to conduct isotopic labelling experiments such that the subsequent protein can be used for NMR studies [10]. It should, however, be noted that the relatively low expression levels of GPCRs in *E. coli* is further impacted by such labelling strategies [10]. However, through optimised expression it has been reported that GPCR expression of up to 50 mg/L can be achieved [40]. The genetic amenability and tools available for *E. coli* open possibilities to select GPCR variants with enhanced expression and stability, generate those “locked” in a particular conformation, and also to, potentially, engineer those with completely novel functions [44]. Despite its prokaryotic nature, *E. coli* has clear potential for at least a subset of GPCRs.

### 2.2. Yeast

The fission yeast *S. pombe* and baker’s yeast *S. cerevisiae* are important tools to express and investigate the signalling and stability of GPCRs [45–51], however, the methlyotrophic yeast, *Pichia pastoris* (reclassified as *Komagataella phaffii*), is favored for the overexpression of GPCRs for structural studies [52]. High yields of functional receptors have been expressed [39], including the adenosine 2a receptor [53–55].
5HT5A receptor, beta-2-adrenergic receptor [56] and muscarinic acetylcholine receptor M2 subtype (CHRM2) [57]. In addition, high-resolution crystal structures of the histamine H1 receptor [58] and the adenosine 2a receptor in complex with an antibody Fab fragment [59] have been obtained using the *P. pastoris* expression system as well as other membrane proteins. This has been feasible due to the ease of manipulation and stable integration of expression vectors into *P. pastoris* coupled with its ability to grow to high cell densities on glycerol and to utilize methanol as the sole carbon source [60]. This system allows high levels of protein expression to be induced under the tightly controlled AOX1 promoter [61,62]. Other promoters are also available, including the constitutive glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter as well as emerging novel methanol-inducible, non-methanol inducible and constitutive promoters [63,64]. Several expression vectors and strains are commercially available to optimize protein expression. Commonly used vectors are the pPIC9K, pPICZ or pPICZαlpha, the latter of which contains an α-MF signal sequence derived from *S. cerevisiae* to enhance protein secretion. Expression vectors generally contain genetic, kanamycin or zeocin resistance genes, and auxotrophic markers have also been used for GPCR expression [52,60]. Strains frequently used include the wild type X-33 strain, protease deficient strains (SMD1163, SMD1168 and SMD1165) and auxotrophic strains GS115 and KM71 [11,52,60].

*P. pastoris* is able to perform post translational modifications such as disulphide bond formation, and N and O-linked glycosylation. N-linked glycosylation occurs at the Asn-X-Ser/Thr motif on extracellular domains of GPCRs [65], and in some cases is required for cell surface expression [66], ligand binding and cell signalling [67]. While early steps of *P. pastoris* N-linked glycosylation are similar to the process in mammalian cells [68], it may potentially hypermannosylate the protein which can lead to misfolding, although this is less extensive than in *S. cerevisiae* [69]. It may also glycosylate residues of protein where this would not naturally occur [69,70]. Some GPCRs expressed in *P. pastoris* have therefore been engineered with these sites removed to facilitate crystallisation [58,59]. A study by Yurugi-Kobayashi et al., 2009 [71] which analysed glycosylation-deficient GPCRs demonstrated that while some receptors were expressed with lower functional levels, others were expressed at levels suitable for structural studies when this approach was combined with culture optimisation. *P. pastoris* strains and vectors with humanized N-glycosylation have been developed [68,72], but have not as of yet been applied to GPCR expression. Other modifications to GPCRs expressed by *P. pastoris* include codon optimisation, N and C-terminal truncations [54,59] and T4-lysozyme fusion to intracellular loop 3 (ICL3) [58].

In contrast to mammalian cells, yeast membranes contain ergosterol rather than cholesterol. Membrane cholesterol is thought to be required for the correct function of some GPCRs, and may cause direct conformational changes or indirectly alter membrane properties. Crystal structures suggest that some GPCRs contain specific cholesterol binding sites [73–75]. A humanized *P. pastoris* strain has been engineered which synthesizes cholesterol [76], and could be of benefit for GPCR expression. Cholesterol hemi-succinate, a cholesterol derivative, can also be added to maintain stability [35, 55, 58].

In summary, yeast possess several advantages over other expression systems, including the ability to perform eukaryotic post-translational modifications while being capable of rapid growth to high cell densities on a large scale in relatively cheap media [77]; these aspects make yeast an appealing host, and their use for GPCR expression has significantly improved knowledge of GPCR structure and function.

### 2.3. Insect cell-line (SF9, SF21, Hi5)

In GPCR structural studies, insect cells are the most commonly used expression system to achieve milligram quantities of protein [35,78]. Expression is achieved via infection with a recombinant form of *Autographica californica*; a multiple nuclear polyhedrosis virus. This baculovirus infects the cells and drives the production of the protein of interest, usually via the polyhedrin promoter [79]. The majority of GPCR studies use the *Spodoptera frugiperda* (SF9) or SF21 cell-line, in preference to *Trichoplusia ni* (High Five) cells [78]. However protein expression levels can vary between different cell-lines so screening of cell lines is necessary when using insect cells for structural studies. The advantages of insect cell expression include growth in serum-free shaker cultures, which decreases costs and enables relatively easy scale-up, as well as high yield and the ability to perform most post-translational modifications [79].

A range of different systems have been developed to generate the recombinant baculovirus [79]. Once generated the virus requires titration in order to achieve an appropriate multiplicity of infection (MOI); an excess of virus will kill the cells before they can be harvested [79]. This step is often the most difficult as how to directly quantify virus is unclear and often inaccurate. Viral plaque assays are commonly used but take a minimum of two weeks and, often, their accuracy is questionable [79]. Various alternative approaches have been devised, including flow cytometry and qPCR, but cost, time and variability can still be problematic [80]. Many researchers find that using the virus directly to express protein in SF9 cells and quantifying the expression level is quicker and more accurate. However, once the virus has been generated and titered it can be stored for a number of years at 4 °C and much longer at ~ 80 °C. More virus can also be generated by infecting the cells with a high MOI and collecting the cell culture media five days post-infection [81]. Initially, it can take up to a month to produce enough baculovirus to drive large scale expression however, once the virus has been generated, protein can be expressed within a week.

One potential disadvantage of insect cell expression arises from differences in lipid composition compared to mammalian cells. Insect cell membranes are low in cholesterol, have very high phosphatidyl-inositol content and no phosphatidylserine [35], and as noted below, protein function is highly dependent on lipid environment [82]. There have also been reports that a proportion of the protein produced can be misfolded [83], or that the lytic pathway of viral infection can cause protein degradation [81]. However, overall it remains one of the key approaches for GPCR overexpression.

#### 2.4. Mammalian cell-line (HEK293, COS)

Membrane proteins are often expressed in insect, bacterial or yeast expression systems due to their high protein yield and expression, which is advantageous for structural studies [84]. High resolution human membrane protein structures have been solved from recombinant proteins derived from these sources, but the protein conformation and modifications may differ from a human protein expressed in human cells. To address these issues, mammalian cell-lines capable of expressing a desired protein have been trialled [85]. The selection of a specific cell-line is determined by whether the expression system represents the near-native environment in which the desired protein is endogenously expressed [84]. GPCRs are heavily post-translationally modified, therefore expressing human GPCRs in mammalian cells is often ideal to characterise their function and pharmacology [35]. For structural biology however, post-translational modifications can be detrimental during crystal formation. Glycosylation sites affect formation of ordered crystals due to the flexibility and heterogeneity of glycan residues [35]. This issue can be solved by mutating the N-glycosylation sites, provided that the conformation of the receptor is still stable [35]. Alternatively, the use of the GnTT™ line which lacks N-acetylgalactosaminyl transferase I activity would possibly enable further control of complex glycans [86].

The native environment in which GPCRs are expressed has an impact on the conformation and pharmacology of these receptors. The phospholipid composition of the native lipid bilayer has an allosteric effect on GPCRs. In the case of the human beta 2 adrenergic receptor in
different liposomes, synthetic phosphatidylglycerol stabilised the active conformation of the receptor [82]. Due to variations in lipid composition between cell-lines of different expression systems, choosing a human cell-line that has a similar lipid composition to that of the endogenous GPCR is important for receptor pharmacology. As cholesterol can allosterically modulate GPCRs [87], its replacement with ergosterol in yeast expression systems can be detrimental. In the case of the human μ-opioid GPCR, ergosterol constrains the receptor in an inactive state, whereas cholesterol stabilises the active state [88]. Post-translational modification is important for GPCR function, where mammalian cells have the correct enzymes for phosphorylation and palmitoylation of human GPCRs [35].

Yields of recombinant protein in non-mammalian expression systems are often higher than mammalian expression systems, therefore optimising the GPCR gene construct for expression is an important first step [35]. Note, however, that higher levels of expression does not necessarily correlate with functional expression and a robust assay for ligand binding and/or signalling can be essential in any optimisation process [83]. This may take the form of traditional radioligand or fluorescent binding assay or could employ NanoBRET e.g. using β1AR tagged with NanoLuc at the N terminus [89]. In any case, GPCR gene constructs are often codon optimised for mammalian cell expression [90]. Kozak sequences (GCCACATGG) and signal peptide sequences can be fused to the 5’ end of the GPCR construct to enhance protein expression and cell surface delivery [90,91]. Subsequently, the optimised construct can be ligated into a plasmid vector, which can be transfected into mammalian cells transiently, or be used to create stable cell lines [35]. While transient transfections with popular reagents give detectable expression at the 48h mark (on average), this can be extended. The BacMam technology uses a modified baculovirus to give expression within 4-6 h of transduction, lasting up to 5-14 days [92].

Finally, not only are stable lines more reproducible in terms of expression within 4–6 h of transduction, lasting up to 5–14 days [92].

Table 2

| GPCR                  | Organism       | Cell-Line | Resolution, Å | PDB Entry |
|----------------------|----------------|-----------|---------------|-----------|
| Angiotensin type II receptor | H. sapiens     | Exp293F   | 2.90          | 6DO1      |
| CB₁ cannabinoid receptor | H. sapiens     | HEK293F   | 2.80          | 5TGZ      |
| Cytomegalovirus U528 | H. sapiens     | HEK       | 2.89          | 4XT1      |
| Leukotriene B₄ receptor | C. porcellus   | HEK293    | 3.70          | SX33      |
| Rhodopsin            | B. taurus      | Cos       | 3.40          | 2J4Y      |
|                      |                |           | 3.30          | 4A4M      |
|                      | H. sapiens     | HEK293S-GeTI | 2.36     | 6FK6      |
|                      |                | HEK293     | 4.38          | 6QNO      |
|                      |                |            | 3.30          | 4ZUJ      |
| Smoothened receptor  | H. sapiens     | HEK293S-GeTI | 3.20     | SL7D      |
|                      |                | HEK293     | 3.84          | 6OT0      |
|                      | M. musculus    | HEK293     | 2.80          | 603C      |

2.5. Drosophila melanogaster

Each of the conventional expression systems detailed above are not without their limitations. One of the major drawbacks associated with all of these systems is the build-up of immature proteins in the intracellular membranes caused by the cell’s failure to properly fold and transport the mature GPCR to the cell surface. This issue can lead to inadequate yields for structural studies thus limiting our understanding of GPCR structure and function [95,96] and obtaining adequate yields of the mature GPCR often requires optimisation of the expression conditions, increasing cost.

The fruit-fly, Drosophila melanogaster, has recently been utilised as an attractive alternative expression system to overcome some of these problems. The system takes advantage of the unique properties and architecture of the fly eye which consists of photoreceptor cells (PRCs) containing membrane stacks called rhabdomeres [97] therefore providing a large surface area for expression and folding of large amounts of membrane-associated proteins [98].

Heterologous expression of proteins within the PRCs is achieved using the well-established GAL4-UAS system [99]. This system allows the tissue-specific expression of transgenes by exploiting the use of the yeast GAL4 protein, a transcription factor that specifically binds to an Upstream Activating Sequence (UAS) to drive expression of its target genes. To express a specific protein in a particular tissue type within the fly, two strains are mated together: the driver-strain which expresses GAL4 from a tissue-specific promoter and the UAS strain which contains the transgene of interest cloned downstream of the GAL4 UAS (Fig. 2). In the resulting offspring, the transgene will be expressed in those specific cells that contain GAL4 [99]. By using a driver-strain that specifically expresses GAL4 within the fly eye, heterologous GPCR expression can be restricted to the PRCs. Generating transgenic flies is relatively easy and comparable in cost to other conventional expression systems. Also, Drosophila culture media for rearing experimental animals is relatively inexpensive and the need to work in sterile conditions is eliminated when working with flies [98].

Drosophila PRCs have been successfully used to express a number of GPCRs [100]; the Drosophila metabotropic glutamate receptor, DmGluRA being first reported. Overexpression of DmGluRA in PRCs resulted in higher yields of mature receptor than obtained using other conventional methods, including insect cell culture. Moreover, toxicity effects of DmGluRA overexpression were not observed in the host cells, overcoming a major limitation of other expression systems. Expressing mammalian mGluRs in the fly eye produced similar yields as expressing DmGluRA, suggesting that this system can be used to express foreign GPCRs from other species including human, rat and Chlamydomonas [98]. Furthermore, expression of the other two classes of GPCRs have now also been successfully reported using this system [100]. Importantly, it should also be noted that scale-up of expression, as required for downstream processes such as crystallisation, can be readily achieved and can sometimes be an issue for other cell culture-based expression systems [77].

Although the use of Drosophila for GPCR expression overcomes several of the major drawbacks associated with more conventional expression systems, it is not without its own limitations. Firstly, this method requires access to fly genetics expertise and facilities for Drosophila culture that if unavailable will require the need for collaboration with specialised laboratories that can provide these services [98]. Additionally, although this system is capable of post-translationally modifying proteins there are differences in some of the modifications that occur in the fly that may be important for GPCR function. An example of this is N-glycosylation, which tends to be less complex in insects and lacking in extended antennae compared to mammals [101,102]. Furthermore, regarding purification of membrane-associated proteins expressed in the fly eye, there is currently a lack of reports describing the use of detergent-free purification methods such as SMALPs using this system [98,100]. This will be an important future
development due to the problems of membrane protein stabilisation associated with using detergents [103,104]. Yet despite these apparent shortfalls, *Drosophila* could prove to be a cheaper and more efficient alternative for functional GPCR expression and purification.

3. Solubilisation and purification

3.1. Detergents

An important barrier to studying GPCRs is the need to solubilise and purify these membrane proteins away from their native bilayer [105]. Ideally, this process should simultaneously retain target proteins in their folded, functional conformations for further *in vitro* study. Surfactant detergents are able to solubilise and extract membrane proteins due to their amphiphilic nature, improving the aqueous solubility of the protein [106]. A plethora of detergents are commercially available with different physicochemical properties; often, a screen is best performed to identify optimal detergents, likely on a protein-by-protein basis [107].

Briefly, detergents fall into three classes based on their polar head group – ionic, zwitterionic and non-ionic. Ionic detergents such as SDS are regarded as harsh, zwitterions are milder (LDAO) while non-ionic detergents are considered mild. The described harshness is derived from the efficacy of disrupting intra- and inter-molecular interactions. While some factors can be scrutinised, such as the critical micelle concentration (CMC) and hydrophilic-lipophilic balance (HLB), some detergents clearly perform well [108]. Overall, the non-ionic alkyl maltoside detergents DM and DDM have been most successful in contributing...
to the resolution of membrane protein structures (approximately 45%) [109], and can be regarded as an evidence-based starting point [11,55,58,59,110].

Detergent monomers will, above the CMC, associate with a biological membrane and undergo a transbilayer mechanism to flip from the outer to inner leaflet [111]. This leads to the formation of lipid-detergent micelles (Fig. 3), the efficacy of which depends on the HLB and size/polarity of the detergent molecule. At this point, the bilayer falls apart resulting in the solubilisation of the membrane. A GPCR's protrusion from the bilayer can aid in the incorporation of detergent monomers due to disruptions in the ordered lipid arrangement. However, this can be opposed by the notion of detergent-resistant membranes [112] – especially in regards to GPCR populations in cholesterol-rich lipid rafts [113].

Following solubilisation, it is often necessary to reduce or remove excess detergent to enable purification and further structural or functional analysis. Several methods are sufficient to achieve this including dialysis, size exclusion and affinity chromatography [111].

Despite their utility thus far, detergents are not without their limitations. Understanding of GPCR structure/function has led to the acknowledgement of the native lipid environment. Not only do the lipids surrounding a receptor provide lateral pressure, directly bound lipids can also be essential to influence active/inactive conformations [55]. As such, detergent micelles do not exert the same lateral pressure, and in some cases, the directly bound lipids required for stability/function are removed. It is therefore preferential to adopt techniques which retain these important components to represent a more biologically realistic reflection of GPCRs and their surroundings; and to prevent destabilisation or inactivation during solubilisation [114].

While several new detergents are being designed/developed, other advances reviewed elsewhere include amphipols [115], nano discs [116] and co-polymers including DIBMA [117] and SMA [118]. Largely, detergents must be chosen empirically, which can be an expensive and protein-demanding approach.

### 3.2. SMALPs

GPCRs are one of the classes of protein that have most frequently defied the attempts by biochemists to purify and characterise them. Poor thermal stability is often blamed for this, and considerable effort and resources have been expended to generate thermostabilized versions of GPCRs, in particular for structural studies [119]. An alternative outlook is that GPCRs are destabilised by detergents. Replacing these with better membrane mimetics could prevent destabilisation of the proteins. Amongst the alternatives that have been proposed to meet this need are styrene maleic acid lipid particles (SMALPs). Styrene maleic acid (SMA) is an amphipathic co-polymer that, when added to lipids, spontaneously assembles into nanoparticles of ~10 nm diameter [120,121]. These nanoparticles consist of SMA polymer surrounding a patch of lipid bilayer (Fig. 3). When SMA is added to biological membranes a similar self-assembly process forms polymer-bound lipid particles containing membrane proteins [122-126].

One of the first reported successes using the SMALP method was the purification and functional characterisation of the adenosine-2A receptor (A2AR) which was overexpressed in both human epithelial kidney (HEK) cells and *Pichia pastoris* (Table 3) [55]. This demonstrated that the protein could be rapidly and effectively purified in a detergent-free manner.

The ligand-binding properties of the A2AR-SMALPs were used to assay its stability under a variety of conditions. Notably, A2AR-SMALPs withstood more than 5 freeze-thaw cycles without reduction in their ligand binding ability. Likewise, A2AR-SMALPs and A2AR in the membrane both retained 75% of their specific ligand binding capacity after up to 15 days of incubation at 4 °C. In detergent, this binding declined to 0% by day 3. Similarly at 37 °C the stability of A2AR in SMALPs far outstripped that of the detergent-solubilised sample. This remarkable
stability under a range of conditions makes A2AR-SMALPs a much more flexible and useful reagent than the detergent-solubilised equivalent.

A2AR was also used in a study of an alternative styrene co-polymer: styrene maleimide (SMI). This has some similar properties and architecture to SMA, but is acid-compatible and can be used in buffers with pH < 7 [127]. By contrast SMA is soluble only above pH 5.8, and is more usually used in buffers of pH 8. A2AR-SMILPs had ligand-binding properties equivalent to the protein in the cell membrane, indicating that SMI also has potential as a reagent for the detergent-free purification of GPCRs. In the same study, the vasopressin receptor (V1aR) also retained its specific ligand-binding properties in SMI-LPs.

The ability to bind ligands is not the only indicator of GPCR function. Perhaps of more importance is the ability of a purified GPCR to recruit/signal to G-proteins and initiate intracellular signalling cascades [128]. One study using SMA has demonstrated that the melatonin receptor (MT1R) and the ghrelin receptor (GHS-R1a) in SMALPs are capable of G-protein activation, arrestin recruitment and ligand binding [129].

To date, there is only one high resolution structure of a GPCR in SMALPs, Haloquadratun waalsbyi bacteriorhodopsin (HWbR). This structure was solved at 2.0 Å resolution using the in meso crystallisation (lipidic cubic phase) methodology [130]. Hence, it is likely that the protein-SMALPs integrated into the bilayers of the cubic phase prior to crystallogenesis. Lipids are visible in the structure, but these are identifiable as monooleins, the lipids used to assemble the cubic phase. In a parallel experiment, bR purified using detergent had a remarkably similar structure to the structure derived from SMA-solubilised bR. Therefore in this case there is an argument that using SMA did not provide additional structural information compared to using detergent. By contrast, a recent structure was solved by cryo-electron microscopy at 3.4 Å resolution of a bacterial respiratory supercomplex purified using SMA [131]. This structure did show specific native lipids bound to the protein, which may be of relevance in understanding the subtleties of its structure and function. This hints that cryo-EM may be a viable approach for solving structures of membrane proteins retaining their native lipids.

Following solubilisation, several purification methods may be employed which have been reviewed elsewhere [132]. Summarised in Table 4, these include gel filtration, ion exchange and affinity chromatography, of which the latter is most popular. While affinity to antibodies or ligands such as lectin can be utilised for membrane proteins, GPCRs expressed in the systems discussed have utilised a range of purification tags. These include poly-histidine [55,58], FLAG [56,133], HA [134], Strep-Tactin [135], Rho [136] and EF1 [137] tags among others. Following detection and affinity chromatography purification, it is possible to obtain the quantities of functional material required for structural studies with these tags [58,59].

More recent advancements include the use of mini-G proteins to study GPCRs in their active conformations [138]. These are engineered GTPase domains of the Gα subunits of G proteins and stabilise the active conformation of the receptor. Not only have they been shown to form stable complexes purified by SEC, N-terminal fusion with GFP allows for successful detection of coupling by FSEC [138]. Such reagents provide huge potential for state-selective purifications.

4. Conclusion

GPCRs remain a challenging component of the membrane protein structural biology field. While the sources of difficulty are gradually being lessened as understanding and technology advance, the dearth of structural information is limiting novel drug design and discovery [4]. Computational biology has greatly enhanced the ability to predict and manipulate GPCR structure, and how this affects their functions. However, in silico experiments remain only a component of the holistic study of membrane proteins; expression and purification are largely required before downstream biochemical and biophysical analysis [8,9,143,144].

As such, and discussed in this review, the expression systems available to GPCR researchers each come with their own benefits and drawbacks. While ease of culture and genetic amenability are undoubtedly attractive qualities, they clearly do not entirely make up for biologically important characteristics such as post-translational modifications. There will always seemingly remain a compromise in the expression system of choice, if only the expense. Regardless of these drawbacks, each traditional system will be preferred for application to certain techniques. For example, post-translational modification may be less desired with regards to crystallisation, but more so for trafficking and functionality.

An interesting alternative to consider is cell-free expression [145]. As cell lysate is used, problems such as toxicity and sequestering of protein to inclusion bodies is avoided. Additionally, this technique allows for modification of GPCRs with unnatural amino acids [146] and is a useful method for NMR labelling [10]. Finally, expression in the eyes of Drosophila offers a promising solution for a scalable production of functional recombinant membrane proteins (Table 5). Currently, as of September 2019, only five PDB entries were derived from expression in Drosophila – none of which were GPCRs. Future work to broaden the

### Table 4

| Purification Technique | Pros | Cons |
|------------------------|------|------|
| Affinity chromatography [139,140] | Can be used if protein molecular weight, charge or hydrophobicity is unknown. High affinity binding can result in high sample purity. | May require a tag or terminal fusion. Washing may remove weakly bound molecules. SMALPs are sensitive to divalent cations. May require further techniques. Limited resolution due to short chromatogram timescale. Inconsistency between columns. Limited to ionizable groups. |
| Gel filtration [141,142] | Efficient separation of large and small molecules. Minimal elution volume. | No sample loss. |
| Ion exchange [139] | Only one charge-based interaction. Predictable elution pattern. | |

### Table 5

| GPCR | Organism | Expression level, pmol/mg total MP |
|------|----------|----------------------------------|
| CCR5 Chemokine receptor | H. sapiens | 555 |
| DmGluRA Metabotropic glutamate receptor | D. melanogaster | 226 |
| mGluR5 Metabotropic glutamate receptor | R. norvegicus | 192 |
| Rh1 Rhodopsin | D. melanogaster | 502 |
| V2R Vasopressin receptor | H. sapiens | > 1000 |
diversity and characterisation of varied GPCRs would invaluably reinforce the use of this emerging technique. Overall, the field is currently in a much stronger position than a few decades ago, and will undoubtedly continue to build upon the methods reviewed here.

Acknowledgements

We are grateful for support from BBSRC (BB/N007417/1, BB/P025927/1, BB/P022685/1, BB/M016668/1, BB/L015846/1, BB/M007529/1, BB/R02152X/1, BB/S004696/1 and BB/T001488/1), H2020 ERA CoBioTech (under grant agreement No. 722361) and M007529/1, BB/R02152X/1, BB/S004696/1 and BB/T001488/1), and will undoubtedly continue to build upon the methods reviewed here.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.pep.2019.105524.

References

[1] B. Kobilka, G protein coupled receptor structure and activation, Biochim. Biophys. Acta 1768 (4) (2007) 794–807.
[2] J. Bockeart, J.P. Pan, Molecular tailoring of G protein-coupled receptors: an evolutionary success, EMBO J. 18 (9) (1999) 1723–1729.
[3] B. Trzaskowski, D. Latke, S. Yuan, U. Ghoshdastider, A. Debinski, S. Filipiek, Action of molecular switches in GPCRs-theoretical and experimental studies, Curr. Med. Chem. 19 (8) (2012) 1090–1109, https://doi.org/10.2174/0929867129320556.
[4] R. Santos, O. Ureu, A. Gautlon, P.A. Bento, R.S. Donadi, C.G. Bologa, A. Harlison, B. Al-Lazikani, A. Hersey, T.I. Oprea, J.P. Overington, A comprehensive map of molecular drug targets, Nat. Rev. Drug Discov. 16 (17) 19–34.
[5] G. Ladds, A.D. Goddard, C. Hill, S. Thornton, J. Davey, Differential effects of RGS proteins on Gαq and Gα12, activity, Cell Signal. 19 (1) (2007) 103–113.
[6] Y.L. Liang, M. Khoshouei, G. Degenati, A. Glakhova, C. Koelle, T.S. Peet, M. Radies, J. Plitzko, W. Baumeister, J.I. Miller, D.L. Hay, A. Christopoulos, C.A. Reynolds, D. Wooten, P.M. Sexton, Cryo-EM structure of the active, Gs-protein complexed, human GPR receptor, Nature 561 (2018) 492–497.
[7] T. Courd, J. Simms, A. Christopoulos, D. Wooten, P.M. Sexton, Improving virtual screening of G protein-coupled receptors via ligand-directed modelling, PLoS Comput. Biol. 13 (11) (2017) e1005819.
[8] J. Birch, D. Axford, J. Foadi, A. Meyer, A. Eckhardt, Y. Thielmann, I. Moraes, The fine art of integral membrane protein crystallisation, Methods 147 (2018) 150–162.
[9] N. Thongin, V. Kargas, J. Clews, R.C. Ford, Cryo-electron microscopy of membrane proteins, Methods 147 (2018) 176–186.
[10] S. Tapaneayukan, A.D. Goddard, J. Oates, C.L. Willis, A. Watts, Solution and solid-state NMR studies of GPCRs and their ligands, Biochim. Biophys. Acta Biomembr. 1808 (6) (2011) 1462–1475.
[11] M.V. Dilworth, M.S. Piel, K.E. Bettany, P. Ma, J.L. Luo, D. Sharples, D.R. Poyner, J.M. Radjainia, J.M. Plitzko, W. Baumeister, L.J. Miller, D.L. Hay, A. Christopoulos, C.A. Reynolds, D. Wooten, P.M. Sexton, Improving virtual screening of G protein-coupled receptors via ligand-directed modelling, PLoS Comput. Biol. 13 (11) (2017) e1005819.
[12] D.K. Atteridge, P.J. Harding, E. Smith, S.R. Ross, A. Watts, Lipid-dependent GPCR dimerization, Methods Cell Biol. 117 (2013) 341–357.
[13] K. Lundstrom, R. Wagner, C. Magg, R. Rudolph, C. Camilliass, A. Desmyter, Mamalian G protein-coupled receptor expression in Escherichia coli: II. Refolding and biophysical characterization of mouse cannabinoid receptor 1 and human parathyroid hormone receptor 1, Anal. Biochem. 401 (1) (2010) 74–80.
[14] D. Milić, D.B. Veprintsev, Large-scale production and protein engineering of G protein-coupled receptors for structural studies, Front. Pharmacol. 31 (6) (2015) 150–162.
[15] N. Bertheleme, P.S. Chae, S. Singhp, D. Mossakowski, M.M. Hann, K.J. Smith, J.A. Hubbard, S.J. Bellew, Unlocking the secrets of the gatekeeper: methods for stabilizing and crystallizing GPCRs, Biochim. Biophys. Acta Biomembr. 1828 (11) (2013) 2583–2591.
[16] A.D. Goddard, A. Watts, Regulation of G protein-coupled receptors by palmitoylation and cholesterol, BMC Biol. 10 (2012) p27.
[17] L.D. Goodman, P.M. Adamsam, A. Watts, Lipid-dependent GPCR dimerization, Methods Cell Biol. 117 (2013) 341–357.
[18] E. Stavridou, S. Reynolds, P. Byrne, Unlocking the secrets of the gatekeeper: methods for stabilizing and crystallizing GPCRs, Biochim. Biophys. Acta Biomembr. 1828 (11) (2013) 2583–2591.
[19] C. Klenk, J. Ehrenmann, M. Schutz, A. Pluckthun, A generic selection system for improved expression and thermostability of G protein-coupled receptors by directed evolution, Sci. Rep. 6 (2016) 21294.
[20] C.A. Sarkar, I. Dodevski, M. Kenig, S. Dudli, A. Mohr, E. Hermans, A. Pluckthun, Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity, PNAS USA 105 (39) (2008) 14808–14813.
[21] G. Skestas, G. Georgiou, Engineering G protein-coupled receptor expression in bacteria, PNAS USA 105 (39) (2008) 14747–14748.
[22] A.G. Facca, L. Testa, G.P. Tocchini Valentinii, The human beta 2-adrenergic receptor expressed in Schizosaccharomyces pombe retains its pharmacological properties, FEBS (Fed. Eur. Biochem. Soc.) Lett. 377 (2) (1995) 140–144.
[23] P. Sander, S. Grunewald, H. Michel, C. Cambillau, The human D2 dopamine receptor in the yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe: a comparative study, FEBS (Fed. Eur. Biochem. Soc.) Lett. 344 (1994) 41–46.
[24] Y. Iguchi, I. Ishii, H. Nakayama, A. Ishikura, K. Izawa, T. Tanaka, C. Ogino, A. Kondo, Control of signalling properties of human somatostatin receptor subtype-5 by additional signal sequences on its amino-terminus in yeast, J. Biol. Chem. 275 (2000) 18577–18583.
[25] H. Harnhi, Y. Nakamura, I. Ishii, A. Kondo, Modifying expression modes of human neurotransin receptor type 1 alters sensing capabilities for agonists in yeast signaling biosensor, Biotechnol. J. 13 (4) (2018) e170522.
[26] S. Togawa, I. Ishii, A. Ishikura, T. Tanaka, C. Ogino, A. Kondo, Importance of
asparaginyl residues at positions 13 and 26 on the amino-terminal domain of human somatostatin receptor subtype-5 in signalling, J. Biochem. 147 (6) (2010) 867–p873, https://doi.org/10.1093/jb/mvq222.

[50] C. Weston, D.R. Foyner, V. Patel, S. Dowell, G. Ladds, Investigating G protein signalling bias for a glucagon-like peptide-1 receptor in yeast, J. Bacteriol. 171 (5) (1989) 3651–p3665, https://doi.org/10.1128/jb.171.5.3651-3665.89.

[51] G. Ladds, K. Davis, E.W. Hillhouse, J. Davey, Modified yeast cells to investigate the coupling of G protein-coupled receptors to specific G proteins, Mol. Microbiol. 47 (3) (2003) 781–792.

[52] B. Byrne, Pichia pastoris as an expression host for membrane protein structural biology,Curr. Opin. Struct. Biol. 32 (2015) 9–17.

[53] N.J. Fraser, Expression and functional purification of a glycosylation deficient version of the human adiponectin 2A receptor for structural studies, Protein Expr. Purif. 49 (1) (2006) 129–p137.

[54] S. Singh, A. Gac, C. Fiez-Vandal, J. Yurugi-Kobayashi, T. Arakawa, H. Iwanari, T. Shimamura, S. Funamoto, T. Yurugi-Kobayashi, C. Ikeda-Suno, Y. Nakada-Signalling bias at the glucagon-like peptide-1 receptor in yeast, Br. J. Pharmacol. 178 (2) (2012) 295–302, https://doi.org/10.1111/bph.12088.

[55] D.N. Wiseman, et al. Protein Expression and Purification 167 (2020) 105524
K.S. Simon, N.L. Pollock, Membrane proteins: is the future disc shaped? Biochem. Soc. Trans. 44 (4) (2016) 1011–1018.

M. Wheatley, J. Charlton, M. Jamshad, S.J. Routledge, S. Bailey, P.J. Le-Borde, M.T. Azam, B.T. Logan, R.M. Bill, T.R. Dafforn, D.R. Poyner,GPCR-stereine maleic acid lipid particles (GPCR-SMALPs): their nature and potential, Biochem. Soc. Trans. 44 (2) (2015) 619–623.

S.C.L. Hall, C. Tognoloni, J. Charlton, E.C. Bragginton, A.J. Rothnie, P. Sridhar, M. Wheatley, T.J. Knowles, T. Arnold, K.J. Edler, T.R. Dafforn, An acid-compatible co-polymer for the solubilisation of membranes and proteins into lipid bilayer-containing nanoparticles, Nanoscale 10 (2018) 10609–10619.

M. Damian, V. Pons, P. Renaud, C.M’Kadmi, B. Delort, L. Hartmann, A.K. Essay, M. Louet, D. Gaspar, K.R.H. Shah, S. Denoyelle, G. Ferry, J.A. Boutin, R. Wagner, J.-A. Fehrentz, J. Martinez, J. Marie, N. Floquet, C. Gales, S. Henry, H.E. Jamm, J.-L. Banerjees, GHK-DSR heteromerization modulates dopamine signalling through and effect on G protein conformation, Proc. Natl. Acad. Sci. 115 (17) (2018) 4501–4506.

C. Logez, M. Damian, C. Legros, C. Dupre, M. Query, S. Mary, R. Wagner, C. M’Kadmi, O. Nosjean, B. Fould, J. Marie, J.-A. Fehrentz, J. Martinez, G. Ferry, J.A. Boutin, J.-L. Banerjees, Detergent-free functionalization of G Protein-Coupled Receptors into nanosomatic lipid particles, Biochemistry 55 (2016) 38–48.

J. Broecker, B.T. Eger, O.P. Ernst, Crystallogenesis of membrane proteins mediated by polymer-bound lipid nanodiscs, Structure 25 (2) (2017) 93844–94392.

J. Charlton, Solubilisation and Characterisation of G Protein-Coupled Receptors Using Styrene Maleic Acid Polymer, PhD thesis University of Birmingham, Birmingham, 2016 Viewed 13/8/19 https://etheses.bham.ac.uk/4652/1/Charlton16PhD.pdf.

S.H. Lin, G. Guidotti, Purification of membrane proteins, Methods Enzymol. 463 (2009) 619–629.

N. André, N. Chervasti, P. Trulut, S. Peffian, G. Zeder-Lutz, T. Maggin, F. Pattus, H. Michel, R. Wagner, C. Reinhart, Enhancing functional production of G protein-coupled receptors in Pichia pastoris to levels required for structural studies via a single expression screen, Protein Sci. 15 (5) (2006) 1115–1126, https://doi.org/10.1101/pdb.602998v06.

L.M. McLaugh, N.J. Fraser, M.J. Main, A. Wise, J. Brown, N. Thompson, R. Solar, M.G. Lee, S.M. Foord, RAMPS regulate the transport and lipid specificity of the calcium-receptor-like receptor, Nature 393 (6683) (1998) p333.

A. Yeliseev, L. Zoubak, T.G.M. Schmidt, Application of Strep-Tactin XT for affinity purification of Twin-Strep-tagged CR2, A G-protein-coupled cannabinoid receptor, Protein Expr. Purif. 131 (2017) 109–118.

S. Locatelli-Hoefs, A. Yeliseev, K. Gawrisch, I. Gorskhova, Surface plasmon resonance applied to G protein-coupled receptors, Biomed. Spectrosc. Imaging 2 (3) (2013) 155–181.

N.N. Mburuchu, L. Zoubak, G. McGaouan, S. Linse, A. Yeliseev, D.J. O’Connell, Simplifying G protein-coupled receptor isolation with a calcium-dependent fragment complementation affinity system, Biochemistry 57 (30) (2018) 4383–4390.

R. Nehme, B. Carpenter, A. Singhal, A. Strege, P.C. Edwards, C.F. White, H. Du, R. Grishammer, C.G. Tate, Mini-G proteins: novel tools for studying GPCRs in their active conformation, PloS One 12 (4) (2017) e0175642.

A. Ninfa, D. Ballou, M. Benore, Fundamental Laboratory Approaches for Biochemistry and Biotechnology, second ed., Wiley, 2009.

P. Kumar, Fundamentals and Techniques of Biophysics and Molecular Biology, second ed., Pathfinder Publication, New Delhi, 2018.

R.H. Garret, C.M. Grisham, Biochemistry, fifth ed., Brooks/Cole, Cengage Learning, Belmont, CA, 2015.

D.A. Skoog, F.J. Holler, S.R. Crouch, ‘Liquid Chromatography’ in Principles of Instrumental Analysis, sixth ed., Thomson Brooks/Cole, Belmont, CA, 2006.

O.K. Castell, P.M. Dijkman, D.N. Wiseman, A.D. Goddard, Single molecule fluorescence for membrane proteins, Methods 147 (2018) 221–228.

R. Uddin, J. Simmers, D.R. Poyner, Functional characterisation of G protein-coupled receptors, Methods 147 (2018) 213–220.

S. Sobhanifar, S. Reckel, E. Körkkö, N. Paukkonen, J. Kivirikko, E. Kärkkäinen, N. Mäkelä, G. Molin, J. Kääriäinen, A. Rautiainen, A. Halonen, L. Wallberg, R. Reimonen, Determination of the stability of G protein-coupled receptors, Mol. Membr. Biochem. 29 (2) (2012) 126–135.

N. Mhurchu, L. Zoubak, G. McGaouan, S. Linse, A. Yeliseev, D.J. O’Connell, Simplifying G protein-coupled receptor isolation with a calcium-dependent fragment complementation affinity system, Biochemistry 57 (30) (2018) 4383–4390.

R. Nehme, B. Carpenter, A. Singhal, A. Strege, P.C. Edwards, C.F. White, H. Du, R. Grishammer, C.G. Tate, Mini-G proteins: novel tools for studying GPCRs in their active conformation, PLoS One 12 (4) (2017) e0175642.

A. Ninfa, D. Ballou, M. Benore, Fundamental Laboratory Approaches for Biochemistry and Biotechnology, second ed., Wiley, 2009.

P. Kumar, Fundamentals and Techniques of Biophysics and Molecular Biology, second ed., Pathfinder Publication, New Delhi, 2018.

R.H. Garret, C.M. Grisham, Biochemistry, fifth ed., Brooks/Cole, Cengage Learning, Belmont, CA, 2015.

D.A. Skoog, F.J. Holler, S.R. Crouch, ‘Liquid Chromatography’ in Principles of Instrumental Analysis, sixth ed., Thomson Brooks/Cole, Belmont, CA, 2006.

O.K. Castell, P.M. Dijkman, D.N. Wiseman, A.D. Goddard, Single molecule fluorescence for membrane proteins, Methods 147 (2018) 221–228.

R. Uddin, J. Simmers, D.R. Poyner, Functional characterisation of G protein-coupled receptors, Methods 147 (2018) 213–220.

S. Sobhanifar, S. Reckel, E. Körkkö, N. Paukkonen, J. Kivirikko, E. Kärkkäinen, N. Mhurchu, L. Zoubak, G. McGaouan, S. Linse, A. Yeliseev, D.J. O’Connell, Simplifying G protein-coupled receptor isolation with a calcium-dependent fragment complementation affinity system, Biochemistry 57 (30) (2018) 4383–4390.

R. Nehme, B. Carpenter, A. Singhal, A. Strege, P.C. Edwards, C.F. White, H. Du, R. Grishammer, C.G. Tate, Mini-G proteins: novel tools for studying GPCRs in their active conformation, PLoS One 12 (4) (2017) e0175642.